Varicella Zoster Virus Envelope Glycoprotein E
Varicella-zoster virus (VZV) glycoprotein E is the most abundant VZV surface glycoprotein and a major target of VZV-specific humoral and cellular immunity, used as the antigen component in the recombinant zoster vaccine (Shingrix). When combined with the AS01B adjuvant system, recombinant glycoprotein E stimulates potent antibody and CD4+ T-cell responses that prevent herpes zoster (shingles) and postherpetic neuralgia. Its use in subunit vaccine format offers advantages over live-attenuated vaccines for immunocompromised patients.
กลไกการออกฤทธิ์
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
คำถามที่พบบ่อย
Varicella-zoster virus (VZV) glycoprotein E is the most abundant VZV surface glycoprotein and a major target of VZV-specific humoral and cellular immunity, used as the antigen component in the recombinant zoster vaccine (Shingrix). When combined with the AS01B adjuvant system, recombinant glycoprotein E stimulates potent antibody and CD4+ T-cell responses that prevent herpes zoster (shingles) and postherpetic neuralgia. Its use in subunit vaccine format offers advantages over live-attenuated vaccines for immunocompromised patients.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Varicella Zoster Virus Envelope Glycoprotein E is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297975. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="varicella-zoster-virus-envelope-glycoprotein-e"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/varicella-zoster-virus-envelope-glycoprotein-e/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/varicella-zoster-virus-envelope-glycoprotein-e/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/varicella-zoster-virus-envelope-glycoprotein-e/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="varicella-zoster-virus-envelope-glycoprotein-e"></drugfyi-drug>